tooluniverse-drug-regulatory

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Drug Regulatory Research

药品监管研究

Regulatory status depends on jurisdiction. FDA approval does not equal EMA approval — check the specific market the user is asking about. Generic availability depends on BOTH patent expiry AND regulatory approval — a patent may have expired but no ANDA may yet be filed or approved. Exclusivity codes (NCE, ODE, PED) can block generics even after patent expiry; always check
FDA_OrangeBook_get_exclusivity
before concluding a generic can enter. A 505(b)(2) NDA is not a generic — it requires its own clinical data and gets its own exclusivity period.
LOOK UP DON'T GUESS: never assume NDA numbers, exclusivity dates, or ATC codes — always call FDAGSRS, Orange Book, and RxClass tools to retrieve current data; regulatory status changes with new approvals and expirations.
Regulatory intelligence for drugs: identify FDA substances, classify drugs by therapeutic category, check approval and generic status, retrieve label sections, and find clinical trials.
监管状态取决于管辖区域。FDA批准并不等同于EMA批准——请确认用户询问的具体市场。仿制药的可用性取决于专利到期和监管批准两者——专利可能已到期,但仿制药申请(ANDA)可能尚未提交或获批。即使专利到期,独占性代码(NCE、ODE、PED)仍可能阻止仿制药进入;在得出仿制药可进入市场的结论前,务必先调用
FDA_OrangeBook_get_exclusivity
工具。505(b)(2) NDA并非仿制药——它需要自身的临床数据,并拥有独立的独占期。
务必查询而非猜测:切勿假设NDA编号、独占性日期或ATC代码——务必调用FDAGSRS、橙皮书和RxClass工具获取最新数据;监管状态会随新批准和到期情况发生变化。
药品监管情报:识别FDA注册物质、按治疗类别对药品进行分类、查询批准与仿制药状态、提取标签内容、查找临床试验。

When to Use

适用场景

  • "What is the FDA regulatory status of semaglutide?"
  • "Is there a generic for Humira?"
  • "What ATC class does metformin belong to?"
  • "Get adverse reactions from the ibuprofen drug label"
  • "When does the patent for Eliquis expire?"
  • "List all drugs in the ACE inhibitor class"
  • "Find clinical trials for a biosimilar of adalimumab"
  • "司美格鲁肽的FDA监管状态是什么?"
  • "修美乐有仿制药吗?"
  • "二甲双胍属于哪个ATC类别?"
  • "获取布洛芬药品标签中的不良反应信息"
  • "阿哌沙班的专利何时到期?"
  • "列出所有ACE抑制剂类药品"
  • "查找阿达木单抗生物类似药的临床试验"

NOT for (use other skills instead)

不适用场景(请使用其他工具)

  • Drug-drug interactions -> Use
    tooluniverse-drug-drug-interaction
  • Pharmacogenomics / dosing by genotype -> Use
    tooluniverse-pharmacogenomics
  • Drug mechanism of action / target binding -> Use
    tooluniverse-drug-mechanism-research
  • Drug repurposing / new indications -> Use
    tooluniverse-drug-repurposing

  • 药物相互作用 -> 使用
    tooluniverse-drug-drug-interaction
  • 药物基因组学 / 基于基因型的给药方案 -> 使用
    tooluniverse-pharmacogenomics
  • 药物作用机制 / 靶点结合 -> 使用
    tooluniverse-drug-mechanism-research
  • 药物重定位 / 新适应症 -> 使用
    tooluniverse-drug-repurposing

Workflow Overview

工作流概述

Input (drug name / brand name / UNII)
  |
  v
Phase 1: Substance Identification  -- FDAGSRS_search_substances, FDAGSRS_get_substance
  |
  v
Phase 2: Drug Classification       -- RxClass_get_drug_classes, RxClass_find_classes
  |
  v
Phase 3: Approval & Generic Status -- FDA_OrangeBook_search_drug, FDA_OrangeBook_check_generic_availability
  |
  v
Phase 4: Patent & Exclusivity      -- FDA_OrangeBook_get_patent_info, FDA_OrangeBook_get_exclusivity
  |
  v
Phase 5: Label Parsing             -- DailyMed_parse_adverse_reactions, DailyMed_parse_dosing, etc.
  |
  v
Phase 6: Clinical Trials           -- search_clinical_trials
  |
  v
Phase 7: Pharmacovigilance         -- FAERS_count_reactions_by_drug_event (param: medicinalproduct)
  |
  v
Phase 8: Literature & Approval     -- PubMed_search_articles, OpenFDA_get_approval_history, RxNorm_get_drug_names
Supplementary tools (not in core phases but useful):
  • OpenFDA_get_approval_history
    — full FDA submission/approval history (requires
    operation
    param)
  • FAERS_count_reactions_by_drug_event
    — top adverse events by report count (param:
    medicinalproduct
    , ALL CAPS)
  • RxNorm_get_drug_names
    — resolve drug to RXCUI and brand names
  • drugbank_vocab_search
    — DrugBank ID, CAS, UNII lookup
  • PubMed_search_articles
    — regulatory and clinical literature

输入(药品名称 / 品牌名 / UNII)
  |
  v
阶段1:物质识别  -- FDAGSRS_search_substances, FDAGSRS_get_substance
  |
  v
阶段2:药品分类       -- RxClass_get_drug_classes, RxClass_find_classes
  |
  v
阶段3:批准与仿制药状态 -- FDA_OrangeBook_search_drug, FDA_OrangeBook_check_generic_availability
  |
  v
阶段4:专利与独占性      -- FDA_OrangeBook_get_patent_info, FDA_OrangeBook_get_exclusivity
  |
  v
阶段5:标签解析             -- DailyMed_parse_adverse_reactions, DailyMed_parse_dosing, etc.
  |
  v
阶段6:临床试验           -- search_clinical_trials
  |
  v
阶段7:药物警戒         -- FAERS_count_reactions_by_drug_event (参数: medicinalproduct)
  |
  v
阶段8:文献与审批     -- PubMed_search_articles, OpenFDA_get_approval_history, RxNorm_get_drug_names
补充工具(不属于核心阶段但实用):
  • OpenFDA_get_approval_history
    — 完整的FDA提交/审批历史(需
    operation
    参数)
  • FAERS_count_reactions_by_drug_event
    — 按报告数量排序的主要不良事件(参数:
    medicinalproduct
    ,需全部大写)
  • RxNorm_get_drug_names
    — 将药品解析为RXCUI和品牌名
  • drugbank_vocab_search
    — DrugBank ID、CAS、UNII查询
  • PubMed_search_articles
    — 监管与临床文献

Phase 1: Substance Identification (FDAGSRS)

阶段1:物质识别(FDAGSRS)

FDAGSRS_search_substances:
query
(string REQUIRED -- drug name, UNII, InChIKey, or formula),
substance_class
(string, optional: "chemical"/"protein"/"nucleic acid"/"polymer"/"mixture"),
limit
(int, 1-50, default 10). Returns
{status, data: {substances: [{unii, name, substance_class, status, cross_references: [{type, value}]}]}}
.
  • cross_references
    contains DrugBank IDs, WHO-ATC codes, CAS numbers, CFR citations.
  • Use to get the official UNII identifier before calling
    FDAGSRS_get_substance
    .
FDAGSRS_get_substance:
unii
(string REQUIRED, 10-char FDA UNII code). Returns complete substance record including all synonyms, names, structure, and cross-references.
  • Provides definitive list of all registered names (INN, USAN, brand, chemical).
FDAGSRS_get_structure:
unii
(string REQUIRED). Returns
{status, data: {smiles, formula, inchikey, molfile, molecular_weight, stereochemistry, optical_activity}}
.
  • Only works for chemical substances; returns error for biologics, mixtures, polymers.
python
undefined
FDAGSRS_search_substances
query
(必填字符串——药品名称、UNII、InChIKey或分子式),
substance_class
(可选字符串:"chemical"/"protein"/"nucleic acid"/"polymer"/"mixture"),
limit
(整数,1-50,默认10)。 返回
{status, data: {substances: [{unii, name, substance_class, status, cross_references: [{type, value}]}]}}
  • cross_references
    包含DrugBank ID、WHO-ATC代码、CAS编号、CFR引用。
  • 调用
    FDAGSRS_get_substance
    前,需通过此工具获取官方UNII标识符。
FDAGSRS_get_substance
unii
(必填字符串,10位FDA UNII代码)。 返回完整的物质记录,包括所有同义词、名称、结构和交叉引用。
  • 提供所有注册名称的权威列表(INN、USAN、品牌名、化学名)。
FDAGSRS_get_structure
unii
(必填字符串)。 返回
{status, data: {smiles, formula, inchikey, molfile, molecular_weight, stereochemistry, optical_activity}}
  • 仅适用于化学物质;若为生物制品、混合物或聚合物,将返回错误。
python
undefined

Full substance lookup workflow

完整物质查询工作流

search = tu.tools.FDAGSRS_search_substances(query="semaglutide") unii = search["data"]["substances"][0]["unii"] full = tu.tools.FDAGSRS_get_substance(unii=unii)

---
search = tu.tools.FDAGSRS_search_substances(query="semaglutide") unii = search["data"]["substances"][0]["unii"] full = tu.tools.FDAGSRS_get_substance(unii=unii)

---

Phase 2: Drug Classification (RxClass)

阶段2:药品分类(RxClass)

RxClass_get_drug_classes:
drug_name
(string, drug name),
rxcui
(string, RxNorm RXCUI -- alternative to drug_name),
rela_source
(string, optional: "ATC"/"FDASPL"/"MESH"/"VA"),
limit
(int, default 20). Returns
{status, data: {classes: [{class_id, class_name, class_type, rela}]}}
.
  • Returns ALL classification systems unless
    rela_source
    filters to one.
  • class_type
    values: "ATC1-4", "EPC" (FDA Established Pharmacologic Class), "MoA", "VA", "MESH".
  • Use to find a drug's ATC code, pharmacological class, mechanism of action label.
RxClass_find_classes:
query
(string REQUIRED, keyword e.g., "beta blocker"),
class_type
(string, optional: "ATC1-4"/"EPC"/"MoA"),
limit
(int, default 20). Returns matching drug classes with class IDs.
  • Use when you need to find a class ID before calling
    RxClass_get_class_members
    .
RxClass_get_class_members:
class_id
(string REQUIRED, e.g., "M01AE"),
rela_source
(string, optional: "ATC"/"FDASPL"),
ttys
(string, optional: "IN" for ingredients),
limit
(int, default 50). Returns all drug ingredients in the class with RXCUIs and names.
  • ttys="IN"
    restricts to active ingredient-level entries (recommended).
python
undefined
RxClass_get_drug_classes
drug_name
(字符串,药品名称),
rxcui
(字符串,RxNorm RXCUI——替代drug_name的参数),
rela_source
(可选字符串:"ATC"/"FDASPL"/"MESH"/"VA"),
limit
(整数,默认20)。 返回
{status, data: {classes: [{class_id, class_name, class_type, rela}]}}
  • 除非通过
    rela_source
    筛选,否则会返回所有分类系统的结果。
  • class_type
    取值:"ATC1-4"、"EPC"(FDA确立药理学分类)、"MoA"、"VA"、"MESH"。
  • 用于查找药品的ATC代码、药理学分类、作用机制标签。
RxClass_find_classes
query
(必填字符串,关键词如"beta blocker"),
class_type
(可选字符串:"ATC1-4"/"EPC"/"MoA"),
limit
(整数,默认20)。 返回匹配的药品类别及类别ID。
  • 当需要先获取类别ID再调用
    RxClass_get_class_members
    时使用。
RxClass_get_class_members
class_id
(必填字符串,如"M01AE"),
rela_source
(可选字符串:"ATC"/"FDASPL"),
ttys
(可选字符串:"IN"表示活性成分),
limit
(整数,默认50)。 返回该类别下所有药品活性成分的RXCUIs和名称。
  • 推荐传入
    ttys="IN"
    以限制结果为活性成分层级的条目。
python
undefined

Find all proton pump inhibitors

查找所有质子泵抑制剂

classes = tu.tools.RxClass_find_classes(query="proton pump inhibitor", class_type="EPC") class_id = classes["data"]["classes"][0]["class_id"] members = tu.tools.RxClass_get_class_members(class_id=class_id, ttys="IN")

---
classes = tu.tools.RxClass_find_classes(query="proton pump inhibitor", class_type="EPC") class_id = classes["data"]["classes"][0]["class_id"] members = tu.tools.RxClass_get_class_members(class_id=class_id, ttys="IN")

---

Phase 3: Approval & Generic Status (FDA Orange Book)

阶段3:批准与仿制药状态(FDA橙皮书)

FDA_OrangeBook_search_drug:
brand_name
(string),
generic_name
(string),
application_number
(string),
limit
(int, default 10). Returns
{status, data: {products: [{brand_name, generic_name, dosage_form, strength, te_code, application_number, approval_date}]}}
.
  • Use brand name (UPPERCASE) or generic name to find NDA/ANDA numbers and approval info.
  • te_code
    : Therapeutic Equivalence code (e.g., "AB" = therapeutically equivalent).
FDA_OrangeBook_check_generic_availability:
brand_name
(string),
generic_name
(string). Returns
{status, data: {reference_listed_drug, generics_available: bool, generics_count, generic_products: [...]}}
.
  • Primary tool for "is there a generic?" questions.
FDA_OrangeBook_get_te_code: No special params beyond
brand_name
/
application_number
. Returns therapeutic equivalence codes for substitutability assessment.
FDA_OrangeBook_get_approval_history:
application_number
(string, e.g., "NDA020402"). Returns chronological approval history including supplemental approvals and label changes.
python
undefined
FDA_OrangeBook_search_drug
brand_name
(字符串),
generic_name
(字符串),
application_number
(字符串),
limit
(整数,默认10)。 返回
{status, data: {products: [{brand_name, generic_name, dosage_form, strength, te_code, application_number, approval_date}]}}
  • 使用品牌名(大写)或通用名查找NDA/ANDA编号及审批信息。
  • te_code
    :治疗等效性代码(如"AB"=治疗等效)。
FDA_OrangeBook_check_generic_availability
brand_name
(字符串),
generic_name
(字符串)。 返回
{status, data: {reference_listed_drug, generics_available: bool, generics_count, generic_products: [...]}}
  • 是回答“是否有仿制药?”问题的核心工具。
FDA_OrangeBook_get_te_code:除
brand_name
/
application_number
外无特殊参数。 返回用于可替代性评估的治疗等效性代码。
FDA_OrangeBook_get_approval_history
application_number
(字符串,如"NDA020402")。 返回按时间排序的审批历史,包括补充审批和标签变更。
python
undefined

Check generic availability

查询仿制药可用性

result = tu.tools.FDA_OrangeBook_check_generic_availability(brand_name="LIPITOR")
result = tu.tools.FDA_OrangeBook_check_generic_availability(brand_name="LIPITOR")

result["data"]["generics_available"] -> True

result["data"]["generics_available"] -> True

result["data"]["generics_count"] -> N

result["data"]["generics_count"] -> N


---

---

Phase 4: Patent & Exclusivity

阶段4:专利与独占性

FDA_OrangeBook_get_patent_info:
application_number
(string),
brand_name
(string). Returns patent information. Note: Full patent numbers and expiration dates require Orange Book data files.
FDA_OrangeBook_get_exclusivity:
application_number
(string),
brand_name
(string). Returns
{status, data: {exclusivities: [{exclusivity_code, exclusivity_date, description}]}}
.
  • exclusivity_code
    values: "NCE" (New Chemical Entity, 5 years), "ODE" (Orphan Drug, 7 years), "PED" (Pediatric, 6 months), "NP" (New Product), "M" (new formulation).

FDA_OrangeBook_get_patent_info
application_number
(字符串),
brand_name
(字符串)。 返回专利信息。注意:完整专利编号和到期日期需要橙皮书数据文件支持。
FDA_OrangeBook_get_exclusivity
application_number
(字符串),
brand_name
(字符串)。 返回
{status, data: {exclusivities: [{exclusivity_code, exclusivity_date, description}]}}
  • exclusivity_code
    取值:"NCE"(新化学实体,5年)、"ODE"(孤儿药,7年)、"PED"(儿科用药,6个月)、"NP"(新产品)、"M"(新剂型)。

Phase 5: Label Parsing (DailyMed)

阶段5:标签解析(DailyMed)

All DailyMed parse tools accept either
setid
(SPL Set ID UUID) OR
drug_name
(auto-lookup). Using
drug_name
is recommended when the setid is unknown.
DailyMed_parse_adverse_reactions:
setid
or
drug_name
. Returns structured adverse reaction table with frequencies and severity.
DailyMed_parse_dosing:
setid
or
drug_name
. Returns dosage and administration section (doses, schedules, renal/hepatic adjustments).
DailyMed_parse_contraindications:
setid
or
drug_name
. Returns contraindications section.
DailyMed_parse_drug_interactions:
setid
or
drug_name
. Returns drug-drug interaction section with clinical management guidance.
DailyMed_parse_clinical_pharmacology:
setid
or
drug_name
. Returns PK/PD data (Cmax, AUC, half-life, protein binding, metabolism pathway).
DailyMed_search_spls:
drug_name
(string), returns SPL Set IDs for that drug. Use to find
setid
when needed explicitly.
python
undefined
所有DailyMed解析工具均接受
setid
(SPL Set ID UUID)或
drug_name
(自动查询)作为参数。 当未知setid时,推荐使用
drug_name
DailyMed_parse_adverse_reactions
setid
drug_name
。返回结构化的不良反应表格,包含发生率和严重程度。
DailyMed_parse_dosing
setid
drug_name
。返回给药方案章节(剂量、给药频次、肾/肝功能调整)。
DailyMed_parse_contraindications
setid
drug_name
。返回禁忌症章节。
DailyMed_parse_drug_interactions
setid
drug_name
。返回药物相互作用章节及临床管理指导。
DailyMed_parse_clinical_pharmacology
setid
drug_name
。返回药代/药效数据(Cmax、AUC、半衰期、蛋白结合率、代谢途径)。
DailyMed_search_spls
drug_name
(字符串),返回该药品的SPL Set ID。当需要明确使用setid时调用。
python
undefined

Parse adverse reactions for apixaban

解析阿哌沙班的不良反应

ae = tu.tools.DailyMed_parse_adverse_reactions(drug_name="apixaban")

---
ae = tu.tools.DailyMed_parse_adverse_reactions(drug_name="apixaban")

---

Phase 6: Clinical Trials

阶段6:临床试验

search_clinical_trials:
condition
(string),
intervention
(string),
query_term
(string),
pageSize
(int, alias:
max_results
/
limit
),
overall_status
(array, alias:
status
). Returns
{status, data: {studies: [{NCT ID, brief_title, brief_summary, overall_status, phase}], total_count}}
.
  • Use
    intervention
    for drug name,
    condition
    for disease.
  • Filter
    overall_status=["RECRUITING"]
    for active enrollment.
  • total_count
    may be None even when results exist; check
    len(studies) > 0
    .
python
undefined
search_clinical_trials
condition
(字符串),
intervention
(字符串),
query_term
(字符串),
pageSize
(整数,别名:
max_results
/
limit
),
overall_status
(数组,别名:
status
)。 返回
{status, data: {studies: [{NCT ID, brief_title, brief_summary, overall_status, phase}], total_count}}
  • 使用
    intervention
    传入药品名称,
    condition
    传入疾病名称。
  • 通过
    overall_status=["RECRUITING"]
    筛选正在招募的试验。
  • 即使存在结果,
    total_count
    也可能为None;需检查
    len(studies) > 0
python
undefined

Find recruiting trials for a biosimilar

查找正在招募的阿达木单抗生物类似药临床试验

trials = tu.tools.search_clinical_trials( intervention="adalimumab biosimilar", overall_status=["RECRUITING"], pageSize=10 )

---
trials = tu.tools.search_clinical_trials( intervention="adalimumab biosimilar", overall_status=["RECRUITING"], pageSize=10 )

---

Example Workflows

示例工作流

Workflow 1: Full Regulatory Profile for a Drug

工作流1:药品完整监管档案

1. FDAGSRS_search_substances(query="apixaban")
   -> UNII, substance class, ATC/DrugBank cross-refs

2. RxClass_get_drug_classes(drug_name="apixaban", rela_source="ATC")
   -> ATC code B01AF02 (direct factor Xa inhibitor)

3. FDA_OrangeBook_search_drug(brand_name="ELIQUIS")
   -> NDA206518, approval date, TE code

4. FDA_OrangeBook_check_generic_availability(brand_name="ELIQUIS")
   -> Generic availability status

5. FDA_OrangeBook_get_exclusivity(brand_name="ELIQUIS")
   -> Exclusivity codes and expiration dates

6. DailyMed_parse_adverse_reactions(drug_name="apixaban")
   -> Bleeding rates and other AEs from label
1. FDAGSRS_search_substances(query="apixaban")
   -> UNII、物质类别、ATC/DrugBank交叉引用

2. RxClass_get_drug_classes(drug_name="apixaban", rela_source="ATC")
   -> ATC代码B01AF02(直接因子Xa抑制剂)

3. FDA_OrangeBook_search_drug(brand_name="ELIQUIS")
   -> NDA206518、批准日期、TE代码

4. FDA_OrangeBook_check_generic_availability(brand_name="ELIQUIS")
   -> 仿制药可用性状态

5. FDA_OrangeBook_get_exclusivity(brand_name="ELIQUIS")
   -> 独占性代码及到期日期

6. DailyMed_parse_adverse_reactions(drug_name="apixaban")
   -> 标签中的出血发生率及其他不良反应

Workflow 2: List All Drugs in a Therapeutic Class

工作流2:列出某治疗类别下的所有药品

1. RxClass_find_classes(query="ACE inhibitor", class_type="EPC")
   -> class_id for "Angiotensin-Converting Enzyme Inhibitor"

2. RxClass_get_class_members(class_id=<id>, ttys="IN")
   -> All ACE inhibitors (enalapril, lisinopril, ramipril, etc.)

3. For each drug: RxClass_get_drug_classes(drug_name=drug)
   -> Confirm ATC code and additional classifications
1. RxClass_find_classes(query="ACE inhibitor", class_type="EPC")
   -> "血管紧张素转换酶抑制剂"的class_id

2. RxClass_get_class_members(class_id=<id>, ttys="IN")
   -> 所有ACE抑制剂(依那普利、赖诺普利、雷米普利等)

3. 对每个药品:RxClass_get_drug_classes(drug_name=drug)
   -> 确认ATC代码及其他分类

Workflow 3: Drug Label Review

工作流3:药品标签审核

1. DailyMed_parse_adverse_reactions(drug_name="metformin")
   -> AE frequencies (GI: lactic acidosis, nausea, diarrhea)

2. DailyMed_parse_contraindications(drug_name="metformin")
   -> eGFR thresholds, renal impairment contraindications

3. DailyMed_parse_drug_interactions(drug_name="metformin")
   -> Iodinated contrast, carbonic anhydrase inhibitor interactions

4. DailyMed_parse_clinical_pharmacology(drug_name="metformin")
   -> Half-life, renal clearance, bioavailability

1. DailyMed_parse_adverse_reactions(drug_name="metformin")
   -> 不良反应发生率(胃肠道:乳酸酸中毒、恶心、腹泻)

2. DailyMed_parse_contraindications(drug_name="metformin")
   -> eGFR阈值、肾功能不全禁忌症

3. DailyMed_parse_drug_interactions(drug_name="metformin")
   -> 含碘造影剂、碳酸酐酶抑制剂相互作用

4. DailyMed_parse_clinical_pharmacology(drug_name="metformin")
   -> 半衰期、肾清除率、生物利用度

Common Mistakes

常见错误

  • Orange Book
    brand_name
    must be UPPERCASE (e.g.,
    "LIPITOR"
    )
  • FDAGSRS_get_substance
    requires UNII, not drug name — call
    FDAGSRS_search_substances
    first
  • FDAGSRS_get_structure
    only works for chemical substances, not biologics
  • RxClass_get_class_members
    : pass
    ttys="IN"
    to restrict to active ingredients
  • search_clinical_trials
    overall_status
    must be an array:
    ["RECRUITING"]

  • 橙皮书的
    brand_name
    必须大写(如
    "LIPITOR"
  • FDAGSRS_get_substance
    需要UNII,而非药品名称——需先调用
    FDAGSRS_search_substances
  • FDAGSRS_get_structure
    仅适用于化学物质,不适用于生物制品
  • RxClass_get_class_members
    :传入
    ttys="IN"
    以限制结果为活性成分
  • search_clinical_trials
    overall_status
    必须为数组格式:
    ["RECRUITING"]

Reasoning Framework

推理框架

Interpretation Guidance

解读指南

Approval pathways: A 505(b)(1) NDA is a full new drug application with complete safety/efficacy data from the sponsor. A 505(b)(2) NDA relies partly on published literature or FDA findings for an already-approved drug (common for reformulations, new routes). An ANDA (Abbreviated NDA) is the generic pathway requiring only bioequivalence to the reference listed drug.
Orange Book patent and exclusivity: NCE (New Chemical Entity) exclusivity gives 5 years of data protection. ODE (Orphan Drug Exclusivity) gives 7 years. PED (Pediatric) adds 6 months to existing patents/exclusivity. A TE code of "AB" means the generic is therapeutically equivalent and substitutable. No TE code or "BX" means substitutability is not established.
DailyMed label sections: The "Adverse Reactions" section distinguishes clinical trial rates (controlled) from post-marketing reports (uncontrolled, signal-only). "Contraindications" are absolute; "Warnings and Precautions" are conditional risks. "Clinical Pharmacology" provides PK parameters (Cmax, AUC, half-life) essential for drug interaction and dosing assessment.
审批路径:505(b)(1) NDA是包含申办方提供的完整安全性/有效性数据的全新药品申请。505(b)(2) NDA部分依赖已发表文献或FDA对已批准药品的研究结果(常见于改良剂型、新给药途径)。ANDA(简化新药申请)是仿制药路径,仅需证明与参比制剂生物等效。
橙皮书专利与独占性:NCE(新化学实体)独占性提供5年数据保护。ODE(孤儿药独占性)提供7年保护。PED(儿科用药)为现有专利/独占性延长6个月。TE代码为"AB"表示仿制药具有治疗等效性,可替代。无TE代码或代码为"BX"表示可替代性未确立。
DailyMed标签章节:“不良反应”章节区分临床试验中的发生率(受控)与上市后报告(非受控,仅为信号)。“禁忌症”为绝对禁忌;“警告与注意事项”为条件性风险。“临床药理学”提供药代动力学参数(Cmax、AUC、半衰期),对药物相互作用和给药方案评估至关重要。

Synthesis Questions

综合问题

A complete drug regulatory report should answer:
  1. What is the current FDA approval status and pathway (NDA vs ANDA vs 505(b)(2))?
  2. Are generic equivalents available, and what is their therapeutic equivalence rating?
  3. When do key patents and exclusivities expire (or have they already)?
  4. What drug class does this belong to (ATC, EPC, MoA), and what are peer drugs in the class?
  5. What are the most clinically significant adverse reactions and contraindications from the label?
一份完整的药品监管报告应回答:
  1. 当前FDA批准状态及路径(NDA vs ANDA vs 505(b)(2))是什么?
  2. 是否有等效仿制药,其治疗等效性评级如何?
  3. 关键专利与独占性何时到期(或是否已到期)?
  4. 该药品属于哪类(ATC、EPC、MoA),同类竞品有哪些?
  5. 标签中最具临床意义的不良反应和禁忌症是什么?